JP7068288B2 - ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形 - Google Patents

４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形 Download PDF

Info

Publication number
JP7068288B2
JP7068288B2 JP2019520040A JP2019520040A JP7068288B2 JP 7068288 B2 JP7068288 B2 JP 7068288B2 JP 2019520040 A JP2019520040 A JP 2019520040A JP 2019520040 A JP2019520040 A JP 2019520040A JP 7068288 B2 JP7068288 B2 JP 7068288B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydroxycyclohexylamino
yloxy
benzothiazole
methylpicolinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019520040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530719A (ja
JP2019530719A5 (enExample
Inventor
グランドゥリ，アルノー
ムリダー ワイコール，リーラダー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019530719A publication Critical patent/JP2019530719A/ja
Publication of JP2019530719A5 publication Critical patent/JP2019530719A5/ja
Application granted granted Critical
Publication of JP7068288B2 publication Critical patent/JP7068288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2019520040A 2016-10-14 2017-10-13 ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形 Expired - Fee Related JP7068288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408358P 2016-10-14 2016-10-14
US62/408,358 2016-10-14
PCT/IB2017/056379 WO2018069892A1 (en) 2016-10-14 2017-10-13 Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide

Publications (3)

Publication Number Publication Date
JP2019530719A JP2019530719A (ja) 2019-10-24
JP2019530719A5 JP2019530719A5 (enExample) 2020-11-19
JP7068288B2 true JP7068288B2 (ja) 2022-05-16

Family

ID=60320932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520040A Expired - Fee Related JP7068288B2 (ja) 2016-10-14 2017-10-13 ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形

Country Status (14)

Country Link
US (1) US10934273B2 (enExample)
EP (1) EP3526217B1 (enExample)
JP (1) JP7068288B2 (enExample)
KR (1) KR20190064589A (enExample)
CN (1) CN109843880B (enExample)
AU (1) AU2017342239B2 (enExample)
BR (1) BR112019006914A2 (enExample)
CA (1) CA3039764A1 (enExample)
CL (1) CL2019001008A1 (enExample)
ES (1) ES2949414T3 (enExample)
IL (1) IL265893A (enExample)
MX (1) MX2019004345A (enExample)
RU (1) RU2019114208A (enExample)
WO (1) WO2018069892A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534410A (ja) 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
CN103501785B (zh) * 2011-05-05 2016-10-26 诺瓦提斯公司 用于治疗脑肿瘤的csf-1r抑制剂
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534410A (ja) 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編，最新 創薬化学 下巻，p.347-365，株式会社 テクノミック，1999年
高田則幸，PHARM STAGE，Vol.6, No.10，2007年，p.20-25

Also Published As

Publication number Publication date
EP3526217B1 (en) 2023-04-19
CN109843880A (zh) 2019-06-04
KR20190064589A (ko) 2019-06-10
RU2019114208A (ru) 2020-11-16
CA3039764A1 (en) 2018-04-19
MX2019004345A (es) 2019-07-01
CN109843880B (zh) 2023-12-01
EP3526217A1 (en) 2019-08-21
WO2018069892A1 (en) 2018-04-19
IL265893A (en) 2019-06-30
US10934273B2 (en) 2021-03-02
AU2017342239B2 (en) 2020-05-28
BR112019006914A2 (pt) 2019-07-02
US20200190057A1 (en) 2020-06-18
JP2019530719A (ja) 2019-10-24
CL2019001008A1 (es) 2019-06-21
ES2949414T3 (es) 2023-09-28
RU2019114208A3 (enExample) 2020-11-18
AU2017342239A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
JP7644027B2 (ja) Ｂｔｋ阻害剤の結晶形態
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
EP3016954B1 (en) Crystalline forms of ponatinib hydrochloride
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
EP3430004B1 (en) Solid state forms of nilotinib salts
JP7068288B2 (ja) ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形
KR20190005904A (ko) 3-[2-부틸-1-(2-디에틸아미노-에틸)-1ｈ-벤조이미다졸-5-일]-ｎ-하이드록시-아크릴아미드의 다형체 형태 및 그의 용도
AU2022201921B2 (en) Crystalline forms of a LTA4H inhibitor
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
RU2808992C2 (ru) Кристаллические формы ингибитора lta4h
US20140221656A1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
KR20260003055A (ko) 에베나마이드의 결정형
HK40043235B (en) Crystalline forms of a lta4h inhibitor
HK40043235A (en) Crystalline forms of a lta4h inhibitor
HK40061331B (en) Crystalline forms of a btk inhibitor
HK40061331A (en) Crystalline forms of a btk inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

R150 Certificate of patent or registration of utility model

Ref document number: 7068288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees